Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David L. Hageman is active.

Publication


Featured researches published by David L. Hageman.


Tetrahedron Letters | 1997

Convenient Preparations of t-Butyl Esters and Ethers from t-Butanol

Stephen W. Wright; David L. Hageman; Ann S. Wright; Lester D. McClure

Abstract A one-pot preparation of t-butyl esters and ethers is described that proceeds from the carboxylic acid or alcohol and t-butanol using only anhydrous magnesium sulfate and catalytic sulfuric acid as additional reagents. The method affords t-butyl esters and ethers in good yields and is applicable to a variety of substrates.


Bioorganic & Medicinal Chemistry Letters | 2003

3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.

Stephen W. Wright; Anthony A. Carlo; Dennis E. Danley; David L. Hageman; George A. Karam; Mahmoud N. Mansour; Lester D. McClure; Jayvardhan Pandit; Gayle K. Schulte; Judith L. Treadway; Ing-Kae Wang; Paul H. Bauer

3-(2-Carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid (MDL-29951), an antagonist of the glycine site of the NMDA receptor, has been found to be an allosteric inhibitor of the enzyme fructose 1,6-bisphosphatase. The compound binds at the AMP regulatory site by X-ray crystallography. This represents a new approach to inhibition of fructose 1,6-bisphosphatase and serves as a lead for further drug design.


Bioorganic & Medicinal Chemistry Letters | 2001

Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines

Stephen W. Wright; David L. Hageman; Lester D. McClure; Anthony A. Carlo; Judith L. Treadway; Alan M. Mathiowetz; Jane M. Withka; Paul H. Bauer

Anilinoquinazolines currently of interest as inhibitors of tyrosine kinases have been found to be allosteric inhibitors of the enzyme fructose 1,6-bisphosphatase. These represent a new approach to inhibition of F16BPase and serve as leads for further drug design. Enzyme inhibition is achieved by binding at an unidentified allosteric site.


Tetrahedron Letters | 1996

A convenient modification of the Gassman oxindole synthesis

Stephen W. Wright; Lester D. McClure; David L. Hageman

Abstract A modification of the Gassman oxindole synthesis is described that proceeds from anilines and ethyl (methylsulfinyl)acetate, using oxalyl chloride to activate the sulfoxide to facilitate the formation of the key N - S bonded intermediate. This procedure is particularly convenient for reactions carried out on smaller scales and for anilines that are susceptible to electrophilic halogenation.


Bioorganic & Medicinal Chemistry Letters | 1992

CP-70,030 and CP-75,998: The first non-peptide antagonists of bombesin and gastrin releasing peptide

James J. Valentine; Susumu Nakanishi; David L. Hageman; R.Michael Snider; Robin W. Spencer; Fredric J. Vinick

Abstract CP-70,030 and CP-75,998 were identified in a screening program as compounds able to displace [125I]-gastrin releasing peptide (GRP) from its rat brain receptor. We describe here the syntheses of these compounds and their characterization as bonafide GRP antagonists.


Tetrahedron Letters | 1996

A synthesis of functionalized indoline 2,2-biscarboxylates

Stephen W. Wright; Robert L. Dow; Lester D. McClure; David L. Hageman

Abstract A synthetic approach to a structurally novel series of indoline 2,2-biscarboxylates is described that employs a tandem bis-alkylation strategy to cyclize the indoline heteroring from the bromide 7 and diethyl bromomalonate. The indolines thus prepared may be N-deprotected and further functionalized on the indoline nitrogen.


Journal of Organic Chemistry | 1994

Fluoride-Mediated Boronic Acid Coupling Reactions

Stephen W. Wright; David L. Hageman; Lester D. McClure


Journal of Medicinal Chemistry | 2002

ANILINOQUINAZOLINE INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE BIND AT A NOVEL ALLOSTERIC SITE: SYNTHESIS, IN VITRO CHARACTERIZATION, AND X-RAY CRYSTALLOGRAPHY

Stephen W. Wright; Carlo Aa; Carty; Dennis E. Danley; David L. Hageman; Karam Ga; Levy Cb; Mahmoud N. Mansour; Mathiowetz Am; Lester D. McClure; Nestor Nb; McPherson Rk; Jayvardhan Pandit; Pustilnik Lr; Schulte Gk; Soeller Wc; Judith L. Treadway; Wang Ik; Paul H. Bauer


Journal of Medicinal Chemistry | 1994

5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists.

John A. Lowe; David L. Hageman; Susan E. Drozda; Stafford McLean; Dianne K. Bryce; Rosemary T. Crawford; Stevin H. Zorn; Jean Morrone; Jon Bordner


Bioorganic & Medicinal Chemistry Letters | 2005

5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization

Stephen W. Wright; Virginia L. Rath; Paul E. Genereux; David L. Hageman; Carolyn B. Levy; Lester D. McClure; Scott C. McCoid; R. Kirk McPherson; Teresa M. Schelhorn; Donald E. Wilder; William J. Zavadoski; E. Michael Gibbs; Judith L. Treadway

Collaboration


Dive into the David L. Hageman's collaboration.

Researchain Logo
Decentralizing Knowledge